Biocon Q3 PAT seen up 10% to Rs 94 cr QoQ

22931 Investors following Biocon. Share this News with them.

0

Like this story, share it with millions of investors on M3

Biocon Q3 PAT seen up 10% to Rs 94 cr QoQ

Pharmaceutical firm Biocon is likely to post a profit after tax of Rs 94 crore in the third quarter of FY12, a growth of 10% as compared to Rs 86 crore in the previous quarter.

Post your opinion here

 

0

Tweet

Share on Tumblr

ALSO READ News and Notices about Biocon See interviews with Biocon Management See what other Experts & Brokerages are saying about Biocon See previous Results of Biocon

Pharmaceutical firm Biocon is likely to post a profit after tax of Rs 94 crore in the third quarter of FY12, a growth of 10% as compared to Rs 86 crore in the previous quarter.

Revenues are seen going up by 7% to Rs 552 crore from Rs 513 crore quarter-on-quarter.

EBITDA is expected to go up by 10% to Rs 152 crore in the quarter ended December FY12 versus Rs 138.5 crore in the previous quarter.

Operating profit margin is likely to be at 27.6% versus 27% during the same period.
 
Watch out for:

- Growth to be led by Biopharm + CRAMS

- In Q2 Biopharma grew 21% led by Statins, Immunosuppresants, Insulin + Fidaxomicin API to Optimer and within Branded formulations growth was led by diabetology which grew 46% YoY

-CRAMS has picked up - so expect the momentum to continue, in Q2 it grew 20% YoY to Rs 93 crore

- Licensing income expected to increase 2HFY12 - in 1HFY12 it was Rs 51.1 crore

- Margins will improve YoY due to no Axicorp but QoQ expect it to be stable and possibly pushed up by higher licensing income, increasing supply of Fidaxomicin + higher demand of insupens

- PAT growth in line with Operational Performance

- Company could announce buyback